New biologic agents have changed the paradigm of rheumatoid arthritis treatment, leading to improvement in managing patients' refractory to classical DMARDs. Anti-TNF-alpha is used as first-line treatment in patients failing to respond to classical DMARDs. However, up to 50% of patients fail to respond to these drugs or develop adverse events leading to treatment discontinuation: in these cases the optimal treatment strategy is still a matter of debate even if trying with a second anti-TNF-alpha is considered a good option. We report data of patients switching from a first to a second anti-TNF-alpha from an Italian registry of patients with rheumatoid arthritis, showing that switching is valuable in patients stopping a first anti-TNF alpha drug. The patients with higher disease activity levels and those stopping the first anti-TNFa treatment because of a lack of efficacy are very likely to respond to the second treatment.
Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry / R. Caporali, P. Sarzi-Puttini, F. Atzeni, R. Gorla, M. Filippini, A. Marchesoni, E. Favalli, F. Bobbio-Pallavicini, C. Montecucco. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - 9:6(2010), pp. 465-469.
Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry
R. CaporaliPrimo
;P. Sarzi-Puttini;E. Favalli;
2010
Abstract
New biologic agents have changed the paradigm of rheumatoid arthritis treatment, leading to improvement in managing patients' refractory to classical DMARDs. Anti-TNF-alpha is used as first-line treatment in patients failing to respond to classical DMARDs. However, up to 50% of patients fail to respond to these drugs or develop adverse events leading to treatment discontinuation: in these cases the optimal treatment strategy is still a matter of debate even if trying with a second anti-TNF-alpha is considered a good option. We report data of patients switching from a first to a second anti-TNF-alpha from an Italian registry of patients with rheumatoid arthritis, showing that switching is valuable in patients stopping a first anti-TNF alpha drug. The patients with higher disease activity levels and those stopping the first anti-TNFa treatment because of a lack of efficacy are very likely to respond to the second treatment.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S1568997209002195-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
164.81 kB
Formato
Adobe PDF
|
164.81 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.